B. Casís

发表

Higher proliferative capacity of T lymphocytes from patients with Crohn disease than from ulcerative colitis is disclosed by use of Herpesvirus saimiri-transformed T-cell lines

J. Martin-Villa, M. Lopez-Santalla, G. Castellano, 2004, Scandinavian journal of gastroenterology.

Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units.

J. Gisbert, E. Espin, A. Dosal, 2014, Journal of Crohn's & colitis.

Rhabdomyolysis and cutaneous necrosis following intravenous vasopressin infusion.

F. Vanaclocha, P. Ortiz, G. Castellano, 1991, Gastroenterology.

Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

C. Taxonera, F. Mesonero, F. Bermejo, 2022, Alimentary pharmacology & therapeutics.

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

C. Taxonera, R. Ferreiro-Iglesias, M. Calvo, 2021, Therapeutic advances in gastroenterology.

Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

J. Mate, J. Gisbert, X. Badia, 2013, Digestive Diseases and Sciences.

Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.

J. Gisbert, M. Chaparro, F. Bermejo, 2011, Gastroenterologia y hepatologia.

Incidence, management, and course of cancer in patients with inflammatory bowel disease.

M. Chaparro, C. Taxonera, A. López-Sanromán, 2015, Journal of Crohn's & colitis.

Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.

J. Mate, J. Gisbert, J. Mendoza, 2008, Gastroenterologia y hepatologia.

Intensification of infliximab therapy in Crohn's disease: efficacy and safety.

J. Mate, J. Gisbert, A. Román, 2012, Journal of Crohn's & colitis.

Predictors of response to infliximab in patients with fistulizing Crohn's disease.

J. Gisbert, J. Mendoza, I. Fernández-Blanco, 2004, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

Collagenous gastrobulbitis and collagenous colitis. Case report and review of the literature.

F. Colina, J. Solis-Herruzo, B. Casís, 1999, Scandinavian journal of gastroenterology.

Current stage in inflammatory bowel disease: What is next?

Á. Masedo, C. Yela, B. Casís, 2015, World journal of gastroenterology.

Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.

J. Mate, J. Gisbert, J. Mendoza, 2007, Hepato-gastroenterology.

Epidemiological Study of Perianal Fistulas in Patients With Crohn's Disease

J. Mate, J. Gisbert, M. Chaparro, 2011 .

Autoimmune Enteropathy in an Adult with Autoimmune Multisystemic Involvement

C. Ballestín, F. Colina, J. Solis-Herruzo, 2002, Scandinavian journal of gastroenterology.

F. Colina, B. Casís, P. Martínez-Montiel, 2013, Digestive Diseases and Sciences.

P157 - Intensification of infliximab (IFX) therapy in Crohn's disease: efficacy and safety

J. Mate, J. Gisbert, M. Chaparro, 2009 .

Refractory hepatic hydrothorax: successful treatment with octreotide.

J. Solís-Herruzo, T. Muñoz-Yagüe, B. Casís, 2005, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

W1313 Adalimumab for Luminal and Perianal Crohn's Disease in Real Practice: A Long-Term Multicenter Study of Effectiveness, Safety and Predictors of Response

J. Gisbert, M. Chaparro, A. Román, 2010 .

[A comparative study of 2 technics of percutaneous endoscopic gastrostomy].

I. Fernández, C. Garfia, G. Castellano, 1995, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.